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Objective: To test usability and optimize the Janssen Autism Knowledge Engine (JAKE®)
system’s components, biosensors, and procedures used for objective measurement of
core and associated symptoms of autism spectrum disorder (ASD) in clinical trials.
Methods: A prospective, observational study of 29 children and adolescents with ASD
using the JAKE system was conducted at three sites in the United States. This study
was designed to establish the feasibility of the JAKE system and to learn practical
aspects of its implementation. In addition to information collected by web and mobile
components, wearable biosensor data were collected both continuously in natural
settings and periodically during a battery of experimental tasks administered in laboratory
settings. This study is registered at clinicaltrials.gov, NCT02299700.
Results: Feedback collected throughout the study allowed future refinements to
be planned for all components of the system. The Autism Behavior Inventory (ABI),
a parent-reported measure of ASD core and associated symptoms, performed well.
Among biosensors studied, the eye-tracker, sleep monitor, and electrocardiogram were
shown to capture high quality data, whereas wireless electroencephalography was
difficult to use due to its form factor. On an exit survey, the majority of parents rated their
overall reaction to JAKE as positive/very positive. No significant device-related events
were reported in the study.
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Conclusion: The results of this study, with the described changes, demonstrate that
the JAKE system is a viable, useful, and safe platform for use in clinical trials of ASD,
justifying larger validation and deployment studies of the optimized system.
Keywords: autism spectrum disorder (ASD), biosensor, biomarker, software, assessment
INTRODUCTION
Autism spectrum disorder (ASD) is a heterogeneous group
of neurodevelopmental disorders characterized by deficits in
social communication and restricted and repetitive behaviors
(American Psychiatric Association, 2013). The prevalence of ASD
in children is estimated to be ∼1% worldwide (Elsabbagh et al.,
2012a; Centers for Disease Control Prevention (CDC)., 2016). In
the United States, the overall estimated ASD prevalence is 14.6
per 1,000 children according to the most recent surveillance data
from the Center for Disease Control’s Autism andDevelopmental
Disabilities Monitoring Network (Christensen et al., 2016).
Therapies for the symptoms of ASD are currently limited to
behavioral interventions and medications that target comorbid
symptoms (e.g., obsessive-compulsive behavior, hyperactivity,
irritability, anxiety, depression). There is no approved agent that
effectively treats the core symptoms of ASD or improves the
natural history of the condition. Furthermore, development of
novel treatments that target core symptoms of ASD, beginning
with study in proof-of-concept clinical trials, is limited by
substantial biological and clinical heterogeneity, lack of a unified
sensitive and objective endpoint for core symptoms, and difficult-
to-quantify risk of potential false negative results, among other
factors (Ghosh et al., 2013). A system that addresses these
operational complexities could utilize various experimental
markers identified by the research field, and integrate them with
broader phenotyping tools.
The purpose of this report is to describe the Janssen
Autism Knowledge Engine (JAKE R©), which is being developed
to provide quantifiable and reproducible measures for use in
treatment monitoring and identification of ASD subgroups.
Suitable measures for JAKE were identified through review of
existing research using biosensors in ASD (Pelphrey et al., 2002;
Wang et al., 2004; Grice et al., 2005; Murias et al., 2007; Coben
et al., 2008; de Wit et al., 2008; Sasson et al., 2008, 2011;
Moscovitch et al., 2011; Pitcher et al., 2011; Chawarska et al.,
2012; Elison et al., 2012; Elsabbagh et al., 2012b; Moore et al.,
2012; Tierney et al., 2012; Tye et al., 2013; Wagner et al., 2013)
and through consultation with experts in each field. We report
Abbreviations: ABI, Autism behavior inventory; ADOS, Autism diagnostic
observation schedule; API, Application protocol interfaces; ASD, Autism spectrum
disorder; CARS-2, Child autism rating scale 2; CSV, Comma-separated values;
eCRF, electronic case report form; ECG, Electrocardiography; EDA, Electrodermal
activity; EEG, Electroencephalography; EMR, Electronic medical records; HAI,
High autism interest; HR, Heart rate; HRV, Heart rate variability; IQ, Intelligence
quotient; IRB, Independent review board; JAKE, Janssen autism knowledge
engine; JBW, JAKE biosensor workbench; K-SADS-PL, Kiddie-SADS-Present and
Lifetime version; LAI, Low autism interest; RDW, Research data warehouse; RRB,
Restricted and repetitive behaviors; SCL, Skin conductance level; SCQ, Social
communication questionnaire; SCR, Skin conductance responses; TD, Typically
developing; UI/UX, User interface/User experience; VABS-II, Vineland adaptive
behavior scale II; VET, Visual exploration task.
herein findings from the first observational, proof-of-principle
study of the complete JAKE system conducted in individuals with
ASD, and focus on the usability and feasibility of the system.
Another aspect of this study, the validity and reliability of the
Autism Behavior Inventory (ABI) as compared with existing
measures is reported elsewhere (Bangerter et al., 2017). ABI is a
parent-reported measure of core and associated ASD symptoms,
developed specifically to measure change in behavior during the
course of an intervention.
This line of research by our group and parallel work
by others [e.g., EU-AIMS (European Autism Interventions1);
Autism Biomarkers Consortium for Clinical Trials–ABC-CT
(Foundation for the National Institutes of Health2)] seeks to
identify biomarkers that stratify the ASD population according
to distinct biological subtypes, thereby providing the foundation
upon which efficacy signals in specific responder subgroups can
be detected. In contradistinction to the EU-AIMS and ABC-
CT initiatives, which are exploring various tools administered
by highly trained clinical research professionals in a laboratory
setting, the aim of JAKE is to employ a mobile and web-
based application coupled with biosensors that can be used by
a community-based clinician and even by non-medical persons
who can be trained to use them in a general clinical or clinical
research setting. This has some similarities to an approach
described by Billeci, also in the early stages of development
(Billeci et al., 2016). The different components of JAKE, as
described further below, are designed to capture sufficiently
variable phenotypes and behaviors across all key domains of
ASD, while providing a high level of utility—effectively making
it simple for caregivers and other observers to record critical
information on improvement or worsening of symptoms and
behaviors.
What Is JAKE?
JAKE, a dynamically updated clinical research system, consists
of several major components (Figure 1), each described below.
Inputs from the JAKE Portal and the JAKE Biosensor Array all
feed through the JAKEData Pipeline, where raw data are archived
and feature extraction occurs. Finally, cleaned data and analyses
are stored in the Janssen Research Data Warehouse (Janssen
RDW) and combined with traditional clinical trial databases.
JAKE Portal
The JAKE Portal and mobile apps, both native Android and
iPhone iOS apps, utilizes Microsoft HealthVault (“HealthVault”)
1European Autism Interventions - A Multicentre Study for Developing New
Medications (EU-AIMS). Available online at: http://www.eu-aims.eu/# (Accessed
November 7, 2016).
2Biomarkers Consortium - TheAutismBiomarkers Consortium for Clinical Trials.
Available online at: http://www.fnih.org/whatwe-do/current-research-programs/
biomarkers-consortium-asd (Accessed November 7, 2016).
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FIGURE 1 | Janssen Autism Knowledge Engine.
as its primary data backend, reading and writing health
information only to this record. HealthVault, a publicly available
electronic personal health record system, is used to store
consumer health data, interact with health applications such as
electronic medical records (EMRs), and authorize sharing of
information across caregivers and health care providers. The
use of HealthVault permits the participant or caregiver to retain
access to any data entered using the JAKE Portal, even after the
study has ended. The system is modular and includes robust
application protocol interfaces (APIs) allowing for the potential
to write data to other back-end data store systems.
HealthVault servers are located in controlled Microsoft
facilities, in physically secured cabinets (HealthVault FAQs,
2015). The HealthVault platform has been the subject of security
testing by both Microsoft and third parties, including “white hat
hacker” penetration testing. Connections between the user and
HealthVault (and the JAKE Portal) are encrypted using strong
industry-standard methods.
Described below are several of the key components of the
JAKE Portal.
The JAKE Portal, accessible through most web browsers and
mobile devices, encompasses tools and technologies designed
Frontiers in Neuroscience | www.frontiersin.org 3 September 2017 | Volume 11 | Article 517
Ness et al. JAKE® Multimodal Data Capture System
for use by clinicians and caregivers to log symptoms, record
interventions, and track progress. Each of the JAKE Portal
modules is described below.
The Dashboard or JAKE Portal home page provides a detailed
overview of the participant’s record: displaying upcoming
appointments and study-related tasks and notifications.
The Medical/Developmental History module, filled out by
caregivers, collects a participant’s comprehensive developmental
and medical history. Key sections include a complete family
and demographic history, gross/fine motor, language, and
social development milestones, current providers and therapies,
medications and supplements, as well as many others. In addition
to this electronic record, all information gathered by the module
is printable, allowing the participant or caregiver to share paper
copies of their medical histories easily with new health care
providers.
A Journal, containing a semi-structured, free-text field,
is available and can be used to document daily behaviors.
The journal can help by providing contextual information to
situations—such as highlighting a positive event or identifying
a particular location where a problem behavior always seems to
surface. Entries are stored in chronological order. Journal entries
also become visible as a hover field on the Dashboard chart,
allowing visualization against behavior tracking data. Finally,
the Journal can serve as a method of communication across
caregivers and care providers—users can filter entries to include
just their own or view all entries created about the child on whom
they are reporting (Figures 2A,B).
The ABI is an online rating scale that assesses core
and associated symptoms of ASD, Figure 3, Bangerter
et al., 2017). The ABI can be downloaded in the USA
from https://www.janssenmd.com/ (in the tools/psychiatry
section) and accessed outside the USA via email request to
autismbehaviorinventory@its.jnj.com. In conjunction with
related components of JAKE, it is designed to capture variable
clinical presentations across all key ASD core and associated
domains, while providing a high level of utility—effectively
making it simple for caregivers and other observers to record
critical information on improvement or worsening of symptoms
and behaviors. Scale development began with a group of 160
questions, which were tested and subjected to factor and usability
analyses, resulting in a final set of 97 questions. This set of
questions was further tested and fine-tuned in this study (results
reported by Bangerter et al., 2017). The ABI is intended to be
completed at weekly intervals, or longer. Additionally, parents
were presented with a subset of the behaviors to rate every day
(Daily Tracker).
Companions to the ABI are an Event Tracker (example screen
shot shown in Figure 4) and a Therapy Tracker. In these modules,
caregivers track events (tantrum, stereotypy, social interaction,
etc.) andmedical and other therapies, as well as medications, diet,
and illnesses.
JAKE Biosensor Array
The JAKE Biosensor Array includes selected biosensors to assess
physiological characteristics and behavior related to the core
FIGURE 2 | View of journal and event entries (A) and new journal entry field (B). The child’s name and journal/event entries are fictional, not original.
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FIGURE 3 | Chart indicating biosensor features. Written, informed consent was obtained from the parents for publication of their child’s image. The child’s name is
fictional.
symptoms of ASD. The JAKE Biosensor Array is divided into two
primary components: a set of continuous, wearable biosensors
that gather information on a daily basis, and a set of periodic
biosensors designed to gather feedback during a battery of
experimental tasks administered via computer in a lab setting.
Continuous biosensors and key parameters collected by each
include: (1) wrist-based accelerometry/actigraphy with the aim
of measuring the frequency and durations of repetitive motor
movements or patterns and activity during the day; (2) similar
actigraphy measures, in conjunction with ambient light sensors,
with the aim of assessing sleep onset, quality, and duration; and
(3) electrodermal activity (EDA) sensors, designed to measure
autonomic nervous system arousal.
Periodic biosensors are used only during the time that
a participant is exposed to specific visual stimuli via a
computer screen interface. The key biological measurements
collected include electroencephalography (EEG), eye-tracking,
and electrocardiography (ECG). Table 1 includes examples of
the types of features that were extracted from the periodic
biosensors. The experimental tasks and stimuli (the JAKE
Task Battery) used with the periodic biosensors include tasks
designed specifically to observe differences between ASD and
typically developing (TD) children. While all periodic biosensors
are used throughout administration of the Task Battery,
several tasks focus on a particular measurement, as described
below. EDA is also collected throughout the periodic task
battery.
EEG is primarily examined during presentation of: (1) a video
designed to elicit a resting state (Wang et al., 2013), in which a
participant watches sand falling through an hourglass for 1 min
and 30 s and then rests with eyes closed for the same duration; (2)
short videos [comprised of clips of dynamic social stimuli (faces
and bodies) and non-social stimuli (objects and scenes)] (Pitcher
et al., 2011); (3) a set of photographs depicting different facial
expressions (Pelphrey et al., 2002; Wang et al., 2004; Tottenham
et al., 2009; Moore et al., 2012; Sepeta et al., 2012; Wagner et al.,
2013); and (4) full color photographic images of different human
faces directing their gaze straight at the viewer (direct gaze) or
averted to either right or left (averted gaze) (Grice et al., 2005;
Elsabbagh et al., 2012b; Tye et al., 2013).
Eye-tracking is primarily examined during: (1) video of
a woman engaging in child-directed speech, an upward age
extension of stimuli by Chawarska et al. (2012) that includes
bids for joint attention (Campbell et al., 2014; Plesa-Skwerer
et al., 2016); (2) the Visual Exploration Task (VET) (Sasson
et al., 2008, 2011; Elison et al., 2012) which contains 12 arrays
of 24 images each [including two sets each of social images, high
autism interest (HAI), and low autism interest (LAI) objects],
presented for 10 s, where the participant is free to explore
the array while the eye-tracker monitors the participant’s visual
attention; (3) a Biological Motion Preference task [based on the
work of Annaz et al. (2012) and Jones et al. (2008); see Shic et al.
(2014a, 2015)], which contains two side-by-side videos of moving
dots, one moving in human fashion (biological motion) and the
other moving randomly (non-biological motion) in random left-
right order; and (4) an Activity Monitoring task (Shic et al.,
2011, 2014b) in which a participant views a video recording of
human actors performing a social activity, with visually salient
distractors in the background.
ECG is monitored during the entire battery and assesses
characteristics such as heart rate (HR) and features derived
from it [e.g., heart rate variability (HRV)], with attention to
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FIGURE 4 | Event tracker screen—mobile version.
abnormalities consistent with impairments in the autonomic
nervous system.
To measure cognitive function, the Cogstate Computerized
Test Battery (2016) was included in the JAKE Task Battery
and evaluated in this study. Involved are tests of information
processing speed and fine motor skills, visual attention, visual
recognition memory, working memory, and emotion processing,
to assess ASD-associated neurocognitive deficits (Baron-Cohen
et al., 2001; Surowiecki et al., 2002; Bavin et al., 2005; Mollica
et al., 2005; Crutcher et al., 2016).
The JAKE Task Battery also assesses participant’s facial
affective expression and physiological reactivity to sensory, social,
and emotional stimuli. For the former, a standard web camera
and the iMotions R© EmotientTM FACET (2016) software module
are used to analyze facial expressions across all task presentations
(participant affective expression), with analyses particularly
focused on facial expressions elicited by the presentation of a set
of videos chosen for their humorous visual content. In addition,
the participant is prompted to produce specific emotional facial
expressions in response to words such as “happy” and “sad,”
which are analyzed by FACET.
The JAKE Biosensor Workbench (JBW) is a management
software / hardware platform used for administration of the Task
Battery. The iMotions R© Biometric Research Platform software
(formerly Attention Tool) is used to synchronize data streams
from several periodic biosensors, while presenting the previously
described stimuli. Additional synchronization for the EEG is
provided using the Cedrus StimTrackerTM. Exported results are
merged with offline data sources, curated, and then transmitted
directly to the JAKE Data Pipeline via a secure file transfer
protocol application. The result is time-synchronized integration
and comprehensive analysis of all biosensor data inputs, in
combination with manually-entered data extracted from the
JAKE Portal.
JAKE Data Pipeline
The main objectives the JAKE Data Pipeline addresses are
data extraction, filtering by identified fields of interest,
de-identification of certain free-text fields such as journal
entries, data cleanup, and harmonization, archiving of all raw
data in order to establish an audit trail, fixing identified data
inconsistencies, transforming the native HealthVault XML-
formatted data into relational comma-separated values (CSV)
tables better suitable for data analysis, and finally delivering
output data stream.
Janssen Research Data Warehouse (RDW)
The Janssen RDW is a set of tools, data stores, and data
feeds designed for robust retrieval, storage, and analysis of all
final, cleaned data generated within the JAKE system. Data
residing in the RDW can be mined using fit-for-purpose analytic
tools and strategies to track treatment outcomes and assess
symptom patterns and subpopulations. The data are also being
used to develop new analytic software to interpret significant
biosensor data events. Following a manual de-identification
procedure, subsets of information contained in the Janssen RDW
may be shared with researchers and members of the scientific
community. RDW’s data flow consists of feeds, pre-processing,
feature extractions, transformations, and outputs.
Data feeds include: (1) the JAKE Data Pipeline for the
HealthVault-originated data; (2) a secure file transfer protocol
server for collecting biosensor data; (3) an electronic case report
form (eCRF) assembling information on a participant’s visits and
basic demographic data; (4) internal clinical data repositories;
(5) experts’ assessments on data quality created using specially-
designed data visualization tools; and (6) transferring paper-
based rating scale data collected in traditional eCRFs. Most of the
feeds are automated and executed overnight.
Early Investigation of JAKE
A prospective observational study was conducted at three
sites (two of which are academic universities and the other,
a clinical service provider) to test and optimize the platform
components of the JAKE system, as well as the selected biosensors
and procedures used for objective measurement of core and
associated symptoms of ASD.
Independent Review Boards (Duke University Health
Systems Institutional Review Board, Durham NC and Western
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TABLE 1 | Example features extracted from periodic biosensors.
Eye-tracking EEG ECG EDA
Tobii X2-30, B-Alert® X24 B-Alert® X24 CamnTech Actiwave Cardio
Single-Channel ECG
Q
TM
Sensor
General features:
• Fixations and saccades (velocity based binocular
algorithms)
• % valid time on screen
• % on ROIs (also normalized to % valid time)
• Pupil size
Specific features:
• Biological Motion preference (%), first saccade
orienting (%]) saccade latency, fixation orienting
(%), fixation latency
• VET exploration, preservation, detail orientation,
RQA features
Induced EEG activity (estimated for each electrode
and different brain region)
• Power spectra at different bands (delta, theta,
alpha, beta, gamma)
• Normalized power spectra at different bands
• Brain asymmetry index for different bands
• Coherence between at different bands
ERP:
• Components’ amplitudes with peak- and
area-based methods
• Components’ latencies with peak- and
area-based methods
• HR
• SDNN
• SDSD
• rMSSD
• NN50
• pNN50
• ApEn
• LF HRV
• Normalized LF HRV
• HF HRV
• Normalized HF HRV
• LF/HF HRV
Tonic activity:
• SCL
Phasic activity:
• SCRR
ApEn, approximate entropy; ECG, electrocardiography; EEG, electroencephalography; EDA, electrodermal activity; ERP, event-related potentials; HF, high frequency; HR, heart rate;
HRV, heart rate variability; LF, low frequency; NN50, number of pairs of successive NNs that differ by more than 50 ms; rMSSD, root mean square of successive differences; RQA,
recurrence quantification analysis; pNN50, proportion of NN50 divided by total number of NNs; RQA, recurrence quantification analysis; SCL, skin conductance level; SCRR, skin
conductance response rate; SDNN, standard deviation of normal to normal R-R intervals; SDSD, standard deviation of successive differences; VET, visual exploration task.
Institutional Review Board, Puyallup, WA) approved the
study protocol and its amendments. The study was conducted
in accordance with the ethical principles originating from
the Declaration of Helsinki, consistent with Good Clinical
Practices and applicable regulatory requirements. Parents (or
legal guardians) of all participants provided written informed
consent and minors provided written informed assent before
enrolling in the study. The study is registered at clinicaltrials.gov,
NCT02299700.
MATERIALS AND METHODS
Study Population
The study enrolled children and adolescents with a diagnosis of
ASD according to Diagnostic and Statistical Manual of Mental
Disorders 5th edition, DSM-5 (American Psychiatric Association,
2013), at least a minimum of mild rating on the Child Autism
Rating Scale 2 [CARS-2 (Schopler et al., 2010)], and a measured
composite score on the Vineland Adaptive Behavior Scale II
[VABS-II (Perry and Factor, 1989)] ≥60, the latter [as a proxy
for intelligence quotient (IQ)] to maximize the likelihood of
completion of the task battery. ASD participants were permitted
to receive behavioral and/or pharmacologic intervention for ASD
and comorbid disorders during the course of the study.
TD children with similar demographics (based on sex, age,
and race) compared to ASD participants were also enrolled. The
TD children had a score in the normal range on the Social
Communication Questionnaire (SCQ), had no existing DSM-5
major mental health disorder according to the Kiddie-SADS-
Present and Lifetime Version (K-SADS-PL) (Kaufman et al.,
1997), and were not taking psychotropic medications. The TD
cohort provided normative data for comparison with that from
ASD participants.
Autism Diagnostic Observation Schedule (ADOS) and
Autism Diagnostic Interview-Revised (ADI-R) were not used
for diagnosis and intelligence quotient (IQ) was not captured
in this pilot study, but will be included in future validation
studies. There are also validation plans across a broader range
of functioning levels, which should be possible due to the passive
viewing nature of most of the tasks.
Study Design
The usability of and methods to increase compliance with
biosensors were developed and tested at two sites (Duke
University Medical Center, Durham, NC; Northeastern
University, Boston, MA) over a 1-week period and at one clinical
site (Children’s Specialized Hospital, Toms River, NJ) at a single
visit for a subset of participants. Functionality of JAKE was
evaluated at all three sites (over a 4-week period at Children’s
Specialized Hospital and over 1 week at the other two sites).
Wearable biosensors tested in this study included: (1) child
daytime sensor (QTM Sensor)—a wireless wristband biosensor
worn during all waking hours that recorded changes in EDA, skin
surface temperature, and 3-dimensional acceleration; and (2)
child nighttime sensor (AMI Micro Motionlogger Sleep Watch)
worn during night-time sleep.
Periodic Sensors
EEG data were collected using B-Alert R© X24, a wireless, wet
electrode system that allows participants to move freely. ECG
data were collected using the CamNTechActiwave Cardio Single-
Channel ECG. Eye-tracking data were collected using Tobii
X2-30.
Measures and tasks were specifically chosen to be appropriate
across ages (6 years old to adult) and a broad range of cognitive
functioning (>60 on the VABS). Most tasks were passive viewing
for this purpose. Clinical judgment was used to determine
whether participants could complete the eyes-closed part of the
task, and the Cogstate battery appeared at the end of the work
bench, allowing for opting out as necessary. Additional breaks
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were possible for those who needed them. The cutoff on VABS
was implemented to ensure a level of functioning high enough to
be capable of completing the workbench.
Given the length of the battery (included a broad range of tasks
to enable reduction/refinement, based on performance, in future
versions of JAKE), tasks split into three sets.
Parents completed an exit survey, which assessed the usability
of JAKE. Questions were answered on a 5-point Likert scale (e.g.,
1= very difficult, 5= very easy).
Study Results and Discussion
The study population comprised 29 children and adolescents
with ASD and 6 TD children. A large ASD cohort was deliberately
enrolled to determine the feasibility of administering JAKE to a
heterogeneous group of individuals with ASD; a much smaller
number of TD participants were enrolled to gather comparative
data.
The majority was male and white; their mean age was 10 years
(Table 2). At screening of the ASD participants, the mean
[standard deviation (SD); range] CARS-2 total score was 47.2
(8.45; 24–62) and VABS total score was 73.3 (17.77; 24–111).
Twenty (14 ASD and all 6 TD) of these participated in the
JBW.
Experience with the JAKE System
Our study was designed to establish the feasibility and utility
of the JAKE system and to learn practical aspects of its
implementation; therefore, we do not present results of group
differences between TD and ASD or differences correlating
severity of ASD based on sensor data.
The JAKE system was successful in gathering responses to the
ABI (Bangerter et al., 2017). It also proved feasible for collecting
medical-developmental history of participants, journal entries,
and, to a limited extent, ASD events (such as parent-identified
instances of restricted and repetitive behaviors).
Although data acquisition from the ECG device was excellent,
issues with our EEG and eye-tracking led to only limited data
availability. In no cases were we successful in capturing all
sensor data types in a single participant or across both time
points. Changes to mitigate these deficiencies are described in the
following section.
We present here key aspects of our analytical process and
examples of results from individual participants to showcase
expected findings using the complete system.
EEG recordings were checked to validate that Power
Spectrum Density (PSD) followed a 1/f shape (“pink noise”),
with possible experiment-related band-specific induced activity
[example shown in Figure 5 (Dawson et al., 2012)]. PSD was
estimated following Welch methods in 4 s segments with 75%
overlap convolved with a Hamming window. For averaging
of PSD data, it was requested to obtain at least 30 such
artifact-free segments (with a smaller number for NIMSTIM
Emotional and Biological Motion Preference Tasks) during
which the participant paid attention to the stimulus/screen as
demonstrated by the eye-tracking data (excluding the eyes closed
condition). For averaging of ERP data, it was requested to obtain
TABLE 2 | Demographic characteristics of study participants.
Autism spectrum disorder
N = 29
Typically developing
children N = 6
SEX, N (%)
Male 25 (86.2) 4 (66.7)
Female 4 (13.8) 2 (33.3)
AGE
Mean (SD) 10.1 (5.20) 10.0 (2.83)
Range 4–27 7–14
RACE, N (%)
White 27 (93.1) 6 (100)
Black 0 0
Multiple 2 (6.9) 0
at least 50 (out of 150) baseline-corrected (baseline: from –
200 to 0 ms before correspondent stimuli onset) responses to
stimuli per condition (zero-phase band-pass filtered between 0.1
and 30 Hz) without artifacts and with attention to stimulus
(as demonstrated by eye-tracking data). The possibility of
detecting an N170 component in (100 250) ms after stimulus
onset was evaluated [example shown in Figure 6 (Grice et al.,
2005)].
For eye-tracking, participants were asked to look at the screen
but were not provided with specific instructions on where to
look. A threshold of 50% was applied, with data being considered
not valid, and excluded if the participant was not looking at
the screen for more than half of the time a task was running.
Calibration mapping of participants’ detected eye positions to
points on the screen were conducted at the beginning of each 15
min experimental block using a 5-point calibration procedure.
Raw EDA data were assessed in terms of amplitudes, dropped
signals, sensitivity of measuring skin conductance level (SCL,
tonic activity), and skin conductance responses (SCR, phasic
activity) (exemplar recordings shown in Figure 7). Sensitivity for
capturing phasic activity was participant-dependent, potentially
related to density of eccrine sweat gland differences on the wrist
across participants. It was also noticed that, independent of the
experiment, SCL increased for about 30 min after the device was
placed on a wrist before the signal stabilized, presumably due to
time necessary to establish a consistent moisture barrier.
Based on their responses to an exit survey, the majority of
parents rated their overall reaction to JAKE as positive/very
positive, with most finding navigation through the different parts
of JAKE easy/very easy (Figure 8).
Safety
Overall, the incidence of adverse events was low during the study.
Adverse events were typical of those in people with ASD, and not
related to the JAKE system. Five adverse events were reported for
four subjects (i.e., two events of upper respiratory tract infection
and one event each of aspiration, pyrexia, and tooth infection).
No significant device-related events were reported in the study.
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FIGURE 5 | Power Spectral Density (PSD) for social and non-social stimuli
averaged among central electrode positions for a single TD participant from
the study. Vertical strips denote delta, theta, alpha, beta, and gamma bands.
Alpha power is suppressed and theta power is enhanced during observation
of social stimuli in comparison to non-social ones. For ASD participants,
differences in alpha and theta are expected to be inversed or negligible
(Dawson et al., 2012).
Resolution of Operational Challenges and
Modification of JAKE System
Based on feedback and observation during the study, several
activities focused on identification and resolution of operational
and quality issues to ensure data integrity, protocol compliance,
and safety of study participants. The design learnings based on
our experience from the study were used to modify the JAKE
system in order to improve reliability in future studies (key
examples provided below).
Jake Mobile and Portal
Modifications to the JAKE mobile and portal application were
made following feedback and results of data collection during the
study.
The JAKE Daily Tracker was designed to enable caregivers
to report changes in symptoms and behaviors on a daily basis.
In this study, the Daily Tracker was made up from a subset of
ABI items. Around five items representing a domain, plus an
overall question about that domain, were presented each day in
a similar format to the questions on the ABI. Following feedback
from parents that these daily questions felt repetitive, and were
not always relevant to their child, we developed and introduced a
new approach that enabled parents to select and track behaviors
most relevant for them. The anchors were changed from the
ABI anchors to an 8-point sliding scale, which was simple and
quick to complete (Figure 9) and had a different feel to the scales
parents were completing on a less regular basis. The number of
items to complete each day was reduced to three, plus a general
FIGURE 6 | Event-related responses averaged along parietal electrodes for
facial stimuli with averted and direct gazes for a single ASD participant from
the study. Vertical stripe indicates interval for N170 estimation. Amplitude of
N170 component for averted gaze stimuli is lower than that for direct gaze
stimuli. We expect to see differences in amplitude/latency of N170 between
two stimuli conditions in the ASD population, with no differences for TD
participants (Grice et al., 2005).
overall type of day rating, and this reduced parent burden for
completion.
To increase feedback to and engagement of the caregivers,
a “journey” chart was added to the JAKE Portal home page,
enabling parents to receive feedback on items they entered and
look for relationships between reported behaviors and events.
It is the primary item on the page and shows a visualization
of a participant’s overall type of day, sleep, and three selected
behaviors from the Daily Tracker over time. All five of these items
from the Daily Tracker are plotted on the same chart for the past
10 days, though the end user has the ability to turn “on” and “off”
specific lines to focus more on one or two items at a time.
In order to further validate the changes made to the system,
two sets of usability tests were conducted on JAKE. Usability
testing is typically conducted to obtain impartial user feedback
on a system or system design. This feedback, taken as a
whole, can be collected to identify minor user interface/user
experience (UI/UX) improvements or to determine the direction
of future capabilities/features. Both rounds of JAKE usability
testing included 10 participants of varying demographics. The
tests were all conducted as one-on-one sessions, lasted 1 h and
were facilitated by an external partner who specializes in usability
testing. The target audience for all sessions was a parent of a child
diagnosed with ASD. Scripts were used to ensure consistency
across the tests, but the facilitator was also able to probe
for more information when the user indicated that something
was confusing or unclear. Detailed reports were prepared
summarizing the feedback and UI/UX recommendations based
on the comments.
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FIGURE 7 | Raw EDA data from a single TD participant. The vertical stripes denote the three sets into which the stimuli were divided. Increase in SCL indicates the
participant’s increasing arousal toward the end of the task battery.
Feedback indicated that the charts would provide motivation
to the users, and further justified incorporation into the JAKE
Portal and apps. Feedback was also obtained on the proposed
change of the Daily Tracker to an 8-point scale, and the ability
for parents to select their own behaviors to track. This was viewed
positively by the participants. The color range and additional
icons were also updated as a result of the usability testing.
Additional user testing led to the inclusion of first use cards
to help with chart explanations, improved navigation for the app,
and changes in the order of items for tracking.
We found that caregivers did not frequently enter ASD events,
and when they were entered participants were not always wearing
the actigraph/EDA device, thus making it impossible to correlate
specific events with sensor data. To mitigate this, we added (for
the next study) a 15-min caregiver observation period, twice
weekly, wherein the caregiver is instructed to concentrate on
entering any ASD events and to ensure participants are wearing
the actigraph/EDA sensor.
We also found that there were instances of personally-
identifiable information (PII) being transmitted to the sponsor’s
databases requiring manual deletion. De-identification—the
process of removing PII from JAKE Portal extracts—was
therefore improved as follows: (1) certain fields in the JAKE
Portal were ignored entirely by the JAKE Data Pipeline; and (2)
fields where PII could inadvertently be stored were targeted for
automatic scrubbing, using the DeID utility (PhysioNet, 2016).
Use of Zweena, a third-party data collection service provider,
to help fill out the Medical/Developmental history proved
beneficial and was continued.
Data Review System
A set of tools was created for visual exploratory assessments of
the JAKE-originated HealthVault data and continuous biosensor
data. This included a web-based Site Managers Dashboard to
assess adherence and automatic detection of protocol deviations
on caregiver data entry tasks and tools to show synchronized data
streams on one plot (for example, overlaying raw accelerometer
data with the JAKE-reported events). Automatic data quality
and integrity checks were introduced into the biosensor data
processing pipeline. A dashboard was also created for team
members to monitor biosensor data transfers, track data
integrity, and provide initial assessments of data integrity.
Additional checks were added to ensure the integrity of calculated
data features.
Autism Behavior Inventory (ABI)
The ABI performed well, demonstrating good reliability and
validity (Bangerter et al., 2017). The number of items was reduced
slightly to 73 based on correlations from this study and small
changes were made in wording or examples for items that parents
reported having difficulties understanding.
Clinician investigators had difficulty answering many of the
items on the full ABI tracker as they required in-depth knowledge
of the participant’s daily life. “I don’t know” responses to the ABI
were rare for parents and more frequently given by clinicians.
As a consequence, it was decided that site clinicians would only
complete a brief (short) version of the ABI (ABI-Short or ABI-S),
which was reviewed to ensure that someone who had only limited
contact with the participant could answer the included items. A
15-min site observation period was added to site visits to allow
the site clinician to observe the participant’s interactions and gain
information to help answer items on the ABI-S.
Biosensors
The B-Alert X24 and Q-sensor used in this study were not
included in the next study. The B-Alert X24 was generally
unable to reach acceptable levels of impedance in children
at any site, and there were difficulties with wireless syncing.
The impedance issues might relate to difficulties experienced
by sites in measuring, creating, and positioning the device
with children. These resulted in no complete EEG data sets
being obtained. A different wired device, available in multiple
cap sizes (making it more adaptable for use in both younger
and older participants with varied head size) and with prior
thorough testing on children (Luchinger et al., 2011; Prehn-
Kristensen et al., 2013; Leventon et al., 2014; Cowell and Decety,
2015; Cremone et al., 2015; Leventon and Bauer, 2017) was
selected to use in subsequent studies. Our results underscored
the importance of directly testing all devices thoroughly in
the target population, and not relying on success in healthy
adults. Additionally, the convenience of wireless connectivity
was outweighed by the added failure modes. Device-independent
issues included participants’: (1) inability to sit still without
moving; (2) touching and playing with the EEG cap; and (3)
muscular activity when asked to keep their eyes closed during
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FIGURE 8 | Results of exit survey completed by parents/caregivers of ASD children. (A) Rate your experience navigating and using the different parts of JAKE.
(B) Rate your overall reaction to JAKE. (C) Would you like to use JAKE again? (D) Would you use the symptom tracker outside of a clinical trial (i.e., even if it were not
required)?
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FIGURE 9 | Revised daily tracker. The child’s name and tracker field are
fictional.
one of the resting state conditions. In addition, we found that
attention to stimuli (demonstrated by eye-tracking) dropped over
lengthy experiments, and we used this data to make adjustments
to the length of the battery.
The Q-sensor is no longer commercially available, and so
it was replaced with a different device for the next study.
Observations over the course of the study advised placement of
any EDA device with dry electrodes on the wrist for at least 30
min prior to starting the task battery to allow stabilization of SCL.
The Tobii eye-tracker, AMI Motionlogger, and Actiwave
Cardio ECG provided reliable and valid data, and will be used
in the next study.
JAKE Task Battery
The Cogstate Computerized Test Battery (2016) presented
several technical challenges related to integration with the
rest of the JAKE system. Among them were issues related
to screen resolution (requiring the experimenter to manually
change screen resolution and change the display orientation)
and missing timestamps for stimuli onset (which prevented
synchronization with other biosensors). Additionally, clinicians
administering the tests reported that participants were also
generally unable to tolerate the length of the Task Battery when
including the Cogstate portion (which added an additional 15
min at the end of the battery). These factors led us to remove
Cogstate from the JAKE Task Battery for the next study.
Calibration of the eye-tracker was difficult at times,
particularly with younger participants. We determined that
individuals with ASD are less likely to pay attention to standard
calibration targets such as pulsating circles. This was addressed
by changing the participants’ calibration target from a red dot
to an object of interest (e.g., animated cartoons). Additionally,
an auditory cue (the sound of a tinkle-bell) was added to draw
the participants’ focus to the screen. Additional calibration
screens were also added throughout the stimuli sets to increase
the chance of post-hoc calibration correction and monitoring
of overall calibration quality following breaks or periods of
inattention. To improve our ability to monitor the reliability
of eye-tracking results, a method for automatically recording
calibration outcomes was introduced.
Crosshairs, presented between different stimuli to direct
participants’ attention to the screen, were changed to cartoon
characters placed at the screen’s center on gray background
(or a color adjusted to the background color of the stimuli
sequence) to make them more attractive to children. In order
to keep participants’ attention on the screen during the eyes
direct/averted ERP experiment, they were additionally asked to
count the number of cartoons of a particular type (e.g., “count the
buses”) appearing between stimuli of interest. The presentation
time of the stimuli was set to more than 1 s after the presentation
of the cartoon to ensure that there was no overlap of brain
activity.
Finally, based on clinician feedback and data quality (e.g.,
attention to the screen), which indicated a degradation of
participants’ compliance with JBW over the course of the Task
Battery, it was shortened, and stimuli were divided among the
three sets so at least a portion of data for most stimuli would
be obtained even if participants did not complete all three sets.
Reward schedules for completion of the battery were discussed
with sites, and refined for future studies.
Future Investigation and Possibilities
The current study demonstrates the feasibility and usability of
deploying a relatively inexpensive system of synchronized sensors
to clinical sites typical of those employed in pharmaceutical
drug studies. Despite the described difficulties with some of the
sensors, the experience of the study has demonstrated the overall
practicality of the approach and also enabled necessary changes
to be made to ensure future success in data collection. Two of
the three sites had no experience with EEG, yet, after training,
were able to administer the JBW and transmit useable data that
could be incorporated into typical data processes that are used
in large interventional studies. In general, the lack of reliance
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on external vendors for collecting and transferring data can
dramatically increase the speed of data collection and analysis.
The system is thus practical for use in sponsored pharmaceutical
studies conducted at distributed clinical sites and does not
require a highly specialized network. Experience from the study
also demonstrates that children and adults with a range of ASD
severities (range of CARS-2 total score: 24–62, VABS total score:
24–111) can tolerate 30–45 min duration of the JBW.
Future refinements of the JAKE system will include use
of combinatorial processes and machine learning approaches
to search for new features and associations. For example, the
degree of search (limited frequency of eye position changes) or
pattern (cyclic or repetitive nature) of search in VET may relate
to restricted and repetitive behaviors (RRBs) overall. And, the
emergence of other types of dynamic task/sensor combinations
(e.g., face/construct valid tasks, games with incidental findings,
passive recording approaches that allow for summation of large
patterns of data) may further enhance the utility of the JAKE
system for clinical trials of ASD. Continuing improvements in
sensor technologymay also allow formore effectivemeasurement
of EDA with wrist-based devices and for home-based JBW
administration.
The JAKE system continues to be improved upon and
is currently being validated in a larger observational study,
collecting more robust data with the optimized system. Together
with the ABI (Bangerter et al., 2017), we plan to expand
use of the JAKE system to interventional studies, with the
ultimate goal of making it available so that increasingly more
therapeutic candidates can be sensitively, objectively, and rapidly
tested to identify efficacious interventions for the growing ASD
population.
CONCLUSIONS
The JAKE system aims to identify biomarkers that can stratify
individuals with ASD into homogeneous sub-populations and
to quantifiably and reproducibly measure intervention outcomes
(i.e., improvements of deficits/symptoms in ASD). To this end,
advances in biosensor devices and the JAKE portal software and
processes, the Task Battery, and the RDW were accomplished
over the course of this study. Despite the exploratory nature
of this program of research, and current findings limited by
small sample sizes and missing data, the JAKE system appears
to be a viable platform for use in clinical trials of ASD, with no
safety issues observed, and holds promise in identifying potential
markers of subpopulations and/or measuring change in ASD.
Clinical Significance
This line of research, utilizing multiple sensors and challenge
tasks and from multiple groups [EU-AIMS1; ABC-CT2], could
lead to the identification of biomarkers that can stratify
individuals with ASD into homogeneous sub-populations and
to quantifiably and reproducibly measure intervention outcomes
(i.e., improvements of deficits/symptoms in ASD). This will
enable the conduct of high-quality pharmaceutical studies to
bring treatments for the core symptoms of ASD to the public.
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